<code id='7E48FFFB6D'></code><style id='7E48FFFB6D'></style>
    • <acronym id='7E48FFFB6D'></acronym>
      <center id='7E48FFFB6D'><center id='7E48FFFB6D'><tfoot id='7E48FFFB6D'></tfoot></center><abbr id='7E48FFFB6D'><dir id='7E48FFFB6D'><tfoot id='7E48FFFB6D'></tfoot><noframes id='7E48FFFB6D'>

    • <optgroup id='7E48FFFB6D'><strike id='7E48FFFB6D'><sup id='7E48FFFB6D'></sup></strike><code id='7E48FFFB6D'></code></optgroup>
        1. <b id='7E48FFFB6D'><label id='7E48FFFB6D'><select id='7E48FFFB6D'><dt id='7E48FFFB6D'><span id='7E48FFFB6D'></span></dt></select></label></b><u id='7E48FFFB6D'></u>
          <i id='7E48FFFB6D'><strike id='7E48FFFB6D'><tt id='7E48FFFB6D'><pre id='7E48FFFB6D'></pre></tt></strike></i>

          Home / Wikipedia / knowledge

          knowledge


          knowledge

          author:leisure time    Page View:8439

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In